ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
Clinical trials for ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene therapy trial targets tough T-Cell cancers
Disease control Recruiting nowThis early-stage trial tests a new gene therapy for certain T-cell lymphomas that have come back or not responded to treatment. The therapy uses a patient's own white blood cells, modified to attack cancer cells that carry a protein called CCR4. Up to 60 adults will receive the m…
Matched conditions: ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo shows promise for rare lymphoma in Real-World study
Disease control Recruiting nowThis observational study tracks 100 adults in Spain with CD30-positive peripheral T-cell lymphoma who received brentuximab vedotin plus CHP as their first treatment. Researchers will review medical records to see how long patients live without their cancer getting worse, how well…
Matched conditions: ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug cocktail aims to tame deadly transplant complication
Disease control Recruiting nowThis phase 3 trial compares two drug combinations given after a stem cell transplant to prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. The study will enroll 572 adults with blood cancers like leukemia or myelodysplasi…
Matched conditions: ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New pill shows promise in Hard-to-Treat blood cancer
Disease control Recruiting nowThis phase 3 trial tests a new oral drug, soquelitinib, against standard single-agent chemotherapy in 150 adults with relapsed or refractory peripheral T-cell lymphoma. The study aims to see if soquelitinib can delay cancer progression better than current options. Participants ar…
Matched conditions: ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Corvus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New hope for rare lymphoma: targeted drug enasidenib enters phase 2 trial
Disease control Recruiting nowThis study tests enasidenib, a drug that targets cancer cells with a specific IDH2 mutation, in people with angioimmunoblastic T-cell lymphoma (AITL). The drug is given alone or with rituximab. The goal is to see if it safely shrinks tumors. About 25 adults whose lymphoma has ret…
Matched conditions: ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Engineered immune cells from cord blood take on tough lymphoma
Disease control Recruiting nowThis early-stage trial is testing a new treatment for people with relapsed or refractory peripheral T-cell lymphoma, a rare and aggressive blood cancer. The therapy uses immune cells (NK cells) from donated umbilical cord blood that are genetically modified to recognize and attac…
Matched conditions: ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New hope for rare blood cancer: targeted drug plus chemotherapy under study
Disease control Recruiting nowThis phase 2 trial is testing whether adding the targeted drug golidocitinib to standard chemotherapy (CHOP) can better control newly diagnosed peripheral T cell lymphoma, a rare and aggressive blood cancer. About 30 adults will receive the combination, and researchers will monit…
Matched conditions: ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New hope for rare blood cancer: platform trial tests multiple drugs at once
Disease control Recruiting nowThis study is testing three oral drugs—roginolisib, golcadomide, and azacitidine—alone or in combination for people with peripheral T-cell lymphoma that has come back or not responded to treatment. The trial has two phases: Phase 1 finds safe doses, and Phase 2 checks if the drug…
Matched conditions: ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New hope for Tough-to-Treat T-Cell lymphoma? pacritinib trial opens
Disease control Recruiting nowThis study tests a drug called pacritinib in 100 people with T-cell lymphoma that has returned or not responded to prior therapy. The main goal is to see how many patients have their tumors shrink or disappear. Participants take the drug and are monitored with scans and skin asse…
Matched conditions: ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for rare blood cancer: Two-Drug combo trial launches
Disease control Recruiting nowThis phase 3 trial tests whether adding either belinostat or pralatrexate to standard chemotherapy helps people with newly diagnosed peripheral T-cell lymphoma live longer without their cancer getting worse. About 504 participants will be randomly assigned to one of three treatme…
Matched conditions: ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Acrotech Biopharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Vitamin a derivative takes on tough lymphoma
Disease control Recruiting nowThis early-stage trial is testing a new form of fenretinide (a vitamin A-like drug) given by IV for people with T-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The study has two parts: first, finding the safest dose in small groups of patients, …
Matched conditions: ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: SciTech Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New targeted drug combo aims to fight rare lymphoma
Disease control Recruiting nowThis phase 3 trial is testing whether adding the targeted drug tucidinostat to standard CHOP chemotherapy helps people with a rare form of lymphoma called peripheral T-cell lymphoma with TFH phenotype. About 224 newly diagnosed adults will receive either tucidinostat or a placebo…
Matched conditions: ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Chipscreen Biosciences, Ltd. • Aim: Disease control
Last updated Jun 26, 2026 17:20 UTC
-
Massive T-Cell lymphoma database aims to unlock new insights
Knowledge-focused Recruiting nowThis study is creating a large database of information and tissue samples from 1,000 people with T-cell lymphoma. Researchers will use this data to learn more about the disease and how to improve patient outcomes. Participants provide medical information and optional blood and na…
Matched conditions: ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC